Legal & General Group PLC Bolt Biotherapeutics, Inc. Transaction History

Legal & General Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.48 - $2.61 $2,712 - $4,784	-1,833 Closed	0 $0
Q2 2022 Aug 22, 2022	SELL	$1.41 - $2.91 $3,543 - $7,312	-2,513 Reduced 57.82%	1,833 $4,000
Q1 2022 May 16, 2022	SELL	$2.74 - $4.82 $3,090 - $5,436	-1,128 Reduced 20.61%	4,346 $12,000
Q4 2021 Feb 14, 2022	BUY	$4.19 - $13.97 $4,726 - $15,758	1,128 Added 25.95%	5,474 $27,000
Q3 2021 Nov 15, 2021	BUY	$11.15 - $18.6 $38,679 - $64,523	3,469 Added 395.55%	4,346 $55,000
Q2 2021 Aug 12, 2021	SELL	$15.4 - $31.46 $6,421 - $13,118	-417 Reduced 32.23%	877 $14,000
Q1 2021 May 17, 2021	BUY	$25.86 - $39.93 $33,462 - $51,669	1,294 New	1,294 $42,000

19.1M

Ticker BOLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,641,500
Market Cap $18.8M
Description
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.